Introduction
Urolithins are not strictly speaking dietary compounds but catabolic products of ellagitannin (ET) and ellagic acid (EA) metabolism carried out by the gut microbiota. 1 The most relevant urolithin is urolithin A (Uro-A), a non-toxic metabolite 2 that is the final urolithin produced by those subjects belonging to the so-called metabotype-A. 3 Given the extensive and heterogeneous metabolism of ETs and EA in humans, our pioneering studies on urolithins suggested that the plausible in vivo active metabolites after ET and EA consumption could be urolithins. 4 To date, many studies have reported a plethora of in vitro activities, 1, 5 but the causality of urolithins in the systemic in vivo activity observed after ET and(or) EA-rich food consumption has not yet been unequivocally proven. 6 Mounting evidence has demonstrated the anti-inflammatory activity, 7 and the preservation of the gut barrier integrity 7, 8 in murine models after oral Uro-A administration, which is consistent with the fact that the colon is the organ where the highest concentration of urolithins occurs. 9 Remarkably, Ryu et al. 10 reported the increase of muscle function in mice after oral Uro-A administration, but the specific metabolite involved in such an effect in tissues remains elusive.
The phase-II metabolism severely hampers the systemic activity of urolithins, including Uro-A. Oral Uro-A bioavailability and tissue distribution are very low. 11, 12 Circulating free Uro-A concentration is negligible since it is extensively conjugated to yield mainly Uro-A glucuronide (Uro-A glur) derivatives in humans. 1, 5, 13 In contrast to the relevant in vitro activity of Uro-A, conjugated derivatives show much lower activity.
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The low bioavailability, extensive phase-II metabolism and gut microbiota catabolism are common features of dietary phenolic compounds. While the health benefits upon consumption of polyphenols have been widely reported, 18 25, 26 which has been evidenced in vivo in the case of luteolin, 25 curcumin, 27 and especially in quercetin. [28] [29] [30] [31] [32] In the present study, our objective was to explore the 'deconjugation in inflammation' hypothesis in the case of urolithins. To illustrate this, we evaluate here for the first time the tissue deconjugation of Uro-A glur to free Uro-A after oral Uro-A administration in a rat model of systemic inflammation induced by lipopolysaccharide (LPS).
Materials and methods

Materials
Urolithin A (Uro-A) and derived conjugated metabolites ( purity > 98%) were obtained as described elsewhere. 33 Lipopolysaccharides (LPS) from Escherichia coli serotype O111: B4 were purchased from Sigma-Aldrich (St Louis, MO, USA). Ketamine (Imalgene 1000) was obtained from Merial Laboratories (Barcelona, Spain). All chemicals and reagents were of analytical grade. Formic acid and HCl were purchased from Panreac (Barcelona, Spain). Organic solvents were obtained from Merck (Darmstadt, Germany), and Milli-Q ultrapure water from Millipore Corp. (Bedford, MA, USA).
Animals and experimental design
The animal ethics committee (University of Murcia, Spain) and the local government (reference A13180503) approved the study. The experimental protocol followed the Directive of the European Council 63/2010/UE, and the Spanish government (RD 53/2013). Male Sprague-Dawley rats (230-250 g) were provided by the Experimental Animal Facility of the University of Murcia. 3-4 rats were housed in a cage in a room with controlled temperature (22 ± 2°C), 55 ± 10% relative humidity, and a 12 h light-dark cycle. Animals were fed with a rat standard chow (Panlab, Barcelona, Spain). Diet and tap water were administered ad libitum until the start of the experiments.
ESI Fig. 1 † shows the design of the experiments. In order to reduce the number of animals in the final experiment, we first explored the maximum plasma glucuronidase activity after intraperitoneal (i.p.) administration of LPS dissolved in phosphate saline buffer (PBS) (20 mg per kg body weight, b.w.) 34 (n = 3) (ESI Fig. 1A †) . The humane endpoint was determined at 5 h after LPS administration. 34 Besides, we also determined the plasma pharmacokinetics of Uro-A and derived metabolites after oral Uro-A administration (n = 3) (ESI The final intervention lasted for 8 hours, in which Uro-A was orally administered to 14 rats by gavage. Three hours after oral Uro-A administration, one group (n = 7) served as the control and the other group (n = 7) received LPS via i.p. (ESI Fig. 1C †) .
At the end of all interventions (both preliminary and final assays), animals were anaesthetised with ketamine (50 mg kg −1 ) and sacrificed by cervical dislocation followed by exsanguination.
Sampling procedure
Blood samples, collected in EDTA-treated tubes, were obtained from the tail vein at 0, 0.5, 1, 2, 3, 4 and 5 hours after i.p. LPS administration in the preliminary experiment, and at 0, 0.5, 1, 2, 5, 7 and 8 hours after administration by gavage of an aqueous Uro-A suspension in both preliminary and final interventions (ESI Fig. 1 †) .
At sacrifice, lungs, kidneys, liver, spleen, prostate, and urinary bladder were removed and snap frozen in liquid nitrogen. The contents of the stomach, small intestine, caecum, and colon were also collected and frozen until further analyses. Urine samples were obtained at sacrifice directly from the bladder and fresh faeces from the distal colon.
Sample processing
Blood was immediately centrifuged at 14 000g for 15 min at 4°C in a Sigma 1-13 microcentrifuge (Braun Biotech. International, Germany). The corresponding plasma samples were extracted with acetonitrile : formic acid (98 : 2, v/v), centrifuged, and the supernatant was reduced to dryness in a speed vacuum concentrator. The evaporated samples were re-suspended in methanol, filtered through a 0.22 µm polyvinylidene fluoride (PVDF) filter and injected in the UPLC-ESI-QTOF-MS equipment.
Urine samples were centrifuged, filtered through a 0.22 µm PVDF filter and diluted with acidified water (0.1% formic acid) before analysis by UPLC-ESI-QTOF-MS.
Lungs, kidneys, liver, spleen, bladder and prostate were extensively washed with PBS to avoid external blood contamination. Tissue samples, as well as the lumen content of the stomach, small intestine, colon and faeces, were processed as previously reported.
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Analysis of urolithins
Analyses were performed on an Agilent 1290 Infinity UPLC system coupled to a 6550 Accurate-Mass quadrupole-time-offlight (QTOF) mass spectrometer (Agilent Technologies, Waldbronn, Germany) using an electrospray interface (Jet Stream Technology). Previously validated methods for the analysis of urolithins in urine, plasma and tissues were used. 9, 33 Free urolithins and their conjugated metabolites were identified and quantified in negative mode by peak area integration of their extracted ion chromatograms (EICs) using available standards. The method was validated for the recovery of metabolites, linearity, precision, accuracy, limits of detection (LOD) and quantification (LOQ) as well as for matrix effects as recently reported. 17 Analysis of β-glucuronidase activity Plasma β-glucuronidase activity was evaluated by measuring the hydrolysis of 4-methylumbelliferyl-glucuronide to the fluorescent molecule 4-methylumbelliferone as described elsewhere. 26 
Statistical analysis
Data were analysed using the SPSS Software 24.0 (SPSS Inc., Chicago, IL, USA). The normality of data distribution was tested with the Shapiro-Wilk test. Pharmacokinetics was evaluated using the software PKSolver, 37 an add-in programme for pharmacokinetic and pharmacodynamic data analysis in MS Excel (Microsoft, Redmond, WA, USA). Pharmacokinetic parameters and differences in the amount of each metabolite between the control and LPS-treated rats in tissues, lumen contents, urine, and blood were compared using either the MannWhitney U test or the two-tailed t-test. Differences in the Uro-A glur/free Uro-A ratios between the control and LPS-treated rats were analysed using the Mann-Whitney U test. Results are shown as the mean ± standard deviation (SD). Significant differences were set at *P < 0.05, **P < 0.01 and ***P < 0.001. A trend toward significance was acknowledged when 0.1 > # P > 0.05. Data plots were created using Sigma Plot 13.0 (Systat Software, San Jose, CA, USA).
Results
Effect of LPS on the oral pharmacokinetics of Uro-A
We first determined the kinetics of LPS-induced plasma β-glucuronidase. Maximum activity was reached after 2 h of LPS administration and remained approximately constant up to 5 h, the previously defined endpoint (ESI Fig. 2 †) . Next, we investigated the oral pharmacokinetics of Uro-A. The main circulating metabolite detected was Uro-A glucuronide (Uro-A glur) ( Fig. 1 ) and, to a lesser extent, Uro-A sulphate (Uro-A sul) (ESI Fig. 3 †) . We could not accurately identify whether the glucuronic moiety was either at the 3-or 8-position in the Uro-A molecule or maybe there was a mixture of both 3-and 8-glucuronides. Although we have the corresponding pure standards, both isomers display the same chromatographic and UV and MS spectroscopic features. Uro-A was poorly bioavailable, and trace amounts (below LOQ) were detected in all the animals, which prevented the quantitative comparison of plasma Uro-A levels between LPS-treated and control rats. When LPS was given after 3 h of oral Uro-A administration, a significant increase in circulating Uro-A glur was observed (Fig. 1) in comparison with control rats despite the variability detected. The pharmacokinetic analysis revealed a significant increase of C max and AUC last in LPS-treated vs. control rats (Table 1) . No effect of LPS was observed in the circulating levels of Uro-A sul (ESI Fig. 3 † and Table 1 ).
Effect of LPS on the distribution of Uro-A and derived metabolites in the gastrointestinal tract
At sacrifice, after 8 h of oral Uro-A administration, there was a tendency towards a lower amount of Uro-A and Uro-A glur in the gastrointestinal tract of LPS-treated vs. control rats, which became statistically significant in the case of Uro-A glur in the small intestine and Uro-A in the cecum (Fig. 2) .
Effect of LPS on the tissue distribution and urinary excretion of Uro-A and derived metabolites
In the tissues, the amount of Uro-A and derived metabolites was higher in LPS-treated vs. control rats (Fig. 3) . The most relevant results were observed in the liver, bladder, lung and spleen tissues where a significant deconjugation of Uro-A glur to Uro-A occurred upon LPS treatment. The amount of free Uro-A detected in the spleen and lungs was roughly equivalent to 2 μM. In contrast, a low and similar amount of metabolites was detected in the prostate (results not shown). Results are shown as mean ± SD. T max , time to reach the peak concentration; C max , peak concentration; T last , last measurable point; C last , last quantifiable concentration; AUC last , area under the plasma concentration-time curve from time 0 to T last ; MRT last , mean residence time (average time for metabolites to reside in the body). 0.1 > # P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001. Regarding the urinary excretion, in contrast to the profile observed in tissues, there was a significant decrease of free Uro-A, Uro-A glur and Uro-A sul in LPS-treated vs. control rats (Fig. 3) . Uro-A diglucuronide and Uro-A sulphoglucuronide were also identified but not quantified due to the lack of standards. The urinary excretion of these metabolites ( peak area) was similar in both groups (results not shown).
The values of the Uro-A glur/Uro-A ratios highlighted the deconjugation process. The ratios were higher in the control than in the LPS-treated rats with the exception of the stomach and cecum contents, reaching statistical significance in all the organs and reservoirs except in the stomach and cecum (Table 2) .
Discussion
We show here for the first time the tissue deconjugation of Uro-A glur to free Uro-A after oral Uro-A administration in a rat model of LPS-induced systemic inflammation. Our results provide further evidence on the 'deconjugation in inflammation' hypothesis, in agreement with previous reports on other phenolics. [25] [26] [27] [28] [29] [30] [31] [32] Urolithins represent a link between diet, gut microbiota and health, which has attracted increasing interest. 1, 5 Many in vitro studies have described a wide range of activities for these molecules in the last decade, especially anti-inflammatory and cancer chemopreventive activities. However, most of these studies are far from representing physiologically relevant conditions. 1, 38 The general pitfall is the assay of free urolithins, usually at high concentration, in cells from systemic organs instead of assaying the corresponding conjugates (glucuronides, sulphates, etc.), which are the molecules that can reach the systemic tissues. In fact, this concern is common for all dietary polyphenols.
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The anti-inflammatory activity and preservation of the barrier integrity of Uro-A in the colon 7, 8 are properties consistent with the high concentrations reached by Uro-A in the colon. 9 However, the metabolites responsible for the systemic effects observed after the oral administration of Uro-A 10, 39 have not yet been described. Uro-A is actively glucuronidated in the enterocyte before entering the bloodstream as Uro-A glur. 5 Remarkably, Uro-A but not Uro-A glur has been reported to be a substrate of the Breast Cancer Resistant Protein (ABCG2/BCRP), 40 a transporter that prevents specific molecules to enter the bloodstream and therefore restricts their distribution into organs. 41 Therefore, the active glucuronidation and the basolateral-apical efflux of Uro-A by BCRP could explain the negligible concentration of Uro-A in the tissues (Fig. 2) . 11, 12, 40 Remarkably, the administration of LPS promoted a higher plasma Uro-A glur concentration vs. control rats (Fig. 1) , which was consistent with the inhibition of ABC transporters by LPS. 42 Therefore, although it may seem paradoxical at first glance, our results are compatible with the fact that LPS treatment favoured the delivery of Uro-A glur to the systemic tissues (inhibition of the BCR transporter), concomitant with a gradual release of free Uro-A from deconjugation by systemic inflammation (Fig. 3 and Table 2 ). The increase of glucuronidase activity in the systemic tissues of endotoxemic animals has been previously reported, 43 which supports the glucuronidase-mediated deconjugation observed in our study. In a parallel scenario, LPS treatment increased benzo(a)pyreneinduced DNA adduct levels in the lung and liver tissues of benzo(a)pyrene inhalatory-exposed mice. 44 This process was associated with the hydrolysis of benzo(a)pyrene glucuronide, which was further confirmed by the mechanistic studies of Shi et al. 45 In the present study, the deconjugation of Uro-A glur to free Uro-A was also supported by the increase of pro-inflammatory cytokines in systemic tissues (results not shown), in agreement with a previous study conducted under the same assay conditions. 34 Although plasma β-glucuronidase also increased Ratios are shown as mean ± SD. Significant differences (P < 0.05) between the control and LPS ratios are bolded. ND, not determined (Uro-A glur was below the quantitation limit). after LPS treatment (ESI Fig. 2 †) , we could not detect the same deconjugation process in the bloodstream. We consider two hypotheses: (i) the low solubility of free Uro-A along with a quick distribution of Uro-A glur to systemic tissues prevented the quantification of this process in plasma, and(or) (ii) the potential adduct formation between Uro-A and blood proteins as reported for other phenolics and derivatives. 46 Following the same rationale, we cannot discard a continuous in situ Uro-A glur to Uro-A deconjugation in systemic tissues, and promoting a possible accumulation of free Uro-A precipitates as a result of its high insolubility in aqueous matrixes. However, the confirmation of the above points requires further research. Finally, we also observed a lower urinary excretion of Uro-A and derived metabolites in endotoxemic rats, which was compatible with the LPS-induced renal failure, a process that can be evident after 3 hours of LPS administration. 47 In the case of the flavonoid quercetin, the deconjugation of quercetin-glucuronide to quercetin has been reported to be mediated by mitochondrial dysfunction in inflammatory macrophages with a relevant deconjugation in the spleen, 30 which agreed with our results in the case of Uro-A (Fig. 3) . Besides, a possible increase of Uro-A, mediated by the deconjugation in circulating macrophages, could also explain the low levels of free Uro-A in plasma samples (i.e., devoid of cells and proteins after acetonitrile precipitation). Although we still do not know the exact mechanisms behind the tissue deconjugation of Uro-A glur to Uro-A, there is a well-known interplay between inflammatory stimuli, mitophagy and promotion/ inhibition of inflammation 48, 49 that could be involved in the deconjugation process of Uro-A glur to Uro-A, and in agreement with the studies on quercetin. 30 
Conclusions
We show here for the first time the inflammatory-mediated tissue deconjugation of Uro-A glur to Uro-A. These results contribute to consolidating the hypothesis of deconjugation in inflammation in the case of urolithins. We are aware that more research is needed to unravel the precise mechanisms underlying the deconjugation process in urolithins. However, our results show that endotoxemia increases free Uro-A in systemic tissues, reaching relevant concentrations, and compatible with in vitro specific biological activities attributed to free Uro-A. The ongoing research in our laboratory will shed some light on this process in the near future.
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